922 related articles for article (PubMed ID: 10193691)
1. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone.
Spencer CM; Markham A
Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
[TBL] [Abstract][Full Text] [Related]
5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone in type II diabetes mellitus.
Sparano N; Seaton TL
Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD; Campbell LK; Campbell RK
Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone. Is it all over?
Wagenaar LJ; Kuck EM; Hoekstra JB
Neth J Med; 1999 Jul; 55(1):4-12. PubMed ID: 10431549
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
Buysschaert M; Bobbioni E; Starkie M; Frith L
Diabet Med; 1999 Feb; 16(2):147-53. PubMed ID: 10229309
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
Parker JC
Adv Drug Deliv Rev; 2002 Nov; 54(9):1173-97. PubMed ID: 12393300
[TBL] [Abstract][Full Text] [Related]
12. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
Schwartz S; Raskin P; Fonseca V; Graveline JF
N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Kosegawa I; Chen S; Awata T; Negishi K; Katayama S
Clin Exp Hypertens; 1999 Apr; 21(3):199-211. PubMed ID: 10225476
[TBL] [Abstract][Full Text] [Related]
15. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
19. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone: an antidiabetic agent.
Chen C
Am J Health Syst Pharm; 1998 May; 55(9):905-25. PubMed ID: 9588250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
